PET Testing Has Utility in the Prescription of Peritoneal Dialysis: PRO
2024

The Role of PET Testing in Peritoneal Dialysis Prescription

publication Evidence: moderate

Author Information

Author(s): Martin J. Schreiber Jr.

Primary Institution: DaVita Kidney Care, Integrated Kidney Care, Denver, Colorado

Hypothesis

Does the peritoneal equilibration test (PET) improve the prescription of peritoneal dialysis (PD) for patients?

Conclusion

The PET provides valuable insights that can enhance the prescription and management of peritoneal dialysis, especially for inexperienced clinicians.

Supporting Evidence

  • The PET provides pathophysiological insights that can guide the design of the initial PD prescription.
  • Data from the PET can help identify at-risk patients and avoid unnecessary treatment complications.
  • Approximately 40% of PD patients drop out of PD programs each year, often transitioning to hemodialysis.

Takeaway

The PET test helps doctors figure out the best way to treat patients on peritoneal dialysis, especially if they are not very experienced.

Limitations

There are currently no well-designed studies comparing dropout rates between programs using PET and those that do not.

Participant Demographics

The article discusses nephrologists and patients with end-stage kidney disease (ESKD), particularly in the United States.

Digital Object Identifier (DOI)

10.34067/KID.0000000000000434

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication